Conditional survival in ovarian cancer

Results from the SEER dataset 1988-2001

Mehee Choi, Clifton D. Fuller, Charles Thomas, Samuel Wang

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Objectives: Survival statistics for patients with ovarian cancer are typically reported in terms of survival from time of diagnosis. For patients who have survived a period of time since diagnosis, however, conditional survival (CS) is a more clinically relevant measure, as it accounts for the changes in risk over time. The purpose of this study was to estimate CS for ovarian cancer patients through analysis of large-scale cancer registry data. Methods: Ovarian cancer cases were extracted from the Surveillance, Epidemiology, and End Results (SEER 17) database from the National Cancer Institute (NCI) for patients diagnosed between 1988-2001. Five-year relative CS calculations were performed with stratification by age, race, stage, histology, and grade for patients who had already survived up to 5 years from diagnosis. Results: The 5-year overall relative CS improved over time for up to 5 years after diagnosis for ovarian cancer patients. The largest gains in CS over time were seen for patients with advanced stage disease, poor grade, and serous and undifferentiated epithelioid histologies. For patients with stage IV disease, 5-year CS more than tripled over the first 5 years of surveillance (17%-56%). Among histological types, patients with undifferentiated epithelioid histology saw 5-year CS rise from 29% at diagnosis to 84% after 5 years. Conclusions: Prognosis improves over time for almost all groups of ovarian cancer patients. For ovarian cancer survivors, CS provides a more relevant measure of prognosis than conventional survival estimates that are made at the time of diagnosis.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalGynecologic Oncology
Volume109
Issue number2
DOIs
StatePublished - May 2008

Fingerprint

Ovarian Neoplasms
Survival
Histology
Datasets
National Cancer Institute (U.S.)
Survivors
Registries
Epidemiology
Databases

Keywords

  • Epidemiologic methods
  • Ovarian cancer
  • Prognosis
  • Survival analysis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Conditional survival in ovarian cancer : Results from the SEER dataset 1988-2001. / Choi, Mehee; Fuller, Clifton D.; Thomas, Charles; Wang, Samuel.

In: Gynecologic Oncology, Vol. 109, No. 2, 05.2008, p. 203-209.

Research output: Contribution to journalArticle

Choi, Mehee ; Fuller, Clifton D. ; Thomas, Charles ; Wang, Samuel. / Conditional survival in ovarian cancer : Results from the SEER dataset 1988-2001. In: Gynecologic Oncology. 2008 ; Vol. 109, No. 2. pp. 203-209.
@article{88ea36d4119a45cdb7539771c9325387,
title = "Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001",
abstract = "Objectives: Survival statistics for patients with ovarian cancer are typically reported in terms of survival from time of diagnosis. For patients who have survived a period of time since diagnosis, however, conditional survival (CS) is a more clinically relevant measure, as it accounts for the changes in risk over time. The purpose of this study was to estimate CS for ovarian cancer patients through analysis of large-scale cancer registry data. Methods: Ovarian cancer cases were extracted from the Surveillance, Epidemiology, and End Results (SEER 17) database from the National Cancer Institute (NCI) for patients diagnosed between 1988-2001. Five-year relative CS calculations were performed with stratification by age, race, stage, histology, and grade for patients who had already survived up to 5 years from diagnosis. Results: The 5-year overall relative CS improved over time for up to 5 years after diagnosis for ovarian cancer patients. The largest gains in CS over time were seen for patients with advanced stage disease, poor grade, and serous and undifferentiated epithelioid histologies. For patients with stage IV disease, 5-year CS more than tripled over the first 5 years of surveillance (17{\%}-56{\%}). Among histological types, patients with undifferentiated epithelioid histology saw 5-year CS rise from 29{\%} at diagnosis to 84{\%} after 5 years. Conclusions: Prognosis improves over time for almost all groups of ovarian cancer patients. For ovarian cancer survivors, CS provides a more relevant measure of prognosis than conventional survival estimates that are made at the time of diagnosis.",
keywords = "Epidemiologic methods, Ovarian cancer, Prognosis, Survival analysis",
author = "Mehee Choi and Fuller, {Clifton D.} and Charles Thomas and Samuel Wang",
year = "2008",
month = "5",
doi = "10.1016/j.ygyno.2008.01.033",
language = "English (US)",
volume = "109",
pages = "203--209",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Conditional survival in ovarian cancer

T2 - Results from the SEER dataset 1988-2001

AU - Choi, Mehee

AU - Fuller, Clifton D.

AU - Thomas, Charles

AU - Wang, Samuel

PY - 2008/5

Y1 - 2008/5

N2 - Objectives: Survival statistics for patients with ovarian cancer are typically reported in terms of survival from time of diagnosis. For patients who have survived a period of time since diagnosis, however, conditional survival (CS) is a more clinically relevant measure, as it accounts for the changes in risk over time. The purpose of this study was to estimate CS for ovarian cancer patients through analysis of large-scale cancer registry data. Methods: Ovarian cancer cases were extracted from the Surveillance, Epidemiology, and End Results (SEER 17) database from the National Cancer Institute (NCI) for patients diagnosed between 1988-2001. Five-year relative CS calculations were performed with stratification by age, race, stage, histology, and grade for patients who had already survived up to 5 years from diagnosis. Results: The 5-year overall relative CS improved over time for up to 5 years after diagnosis for ovarian cancer patients. The largest gains in CS over time were seen for patients with advanced stage disease, poor grade, and serous and undifferentiated epithelioid histologies. For patients with stage IV disease, 5-year CS more than tripled over the first 5 years of surveillance (17%-56%). Among histological types, patients with undifferentiated epithelioid histology saw 5-year CS rise from 29% at diagnosis to 84% after 5 years. Conclusions: Prognosis improves over time for almost all groups of ovarian cancer patients. For ovarian cancer survivors, CS provides a more relevant measure of prognosis than conventional survival estimates that are made at the time of diagnosis.

AB - Objectives: Survival statistics for patients with ovarian cancer are typically reported in terms of survival from time of diagnosis. For patients who have survived a period of time since diagnosis, however, conditional survival (CS) is a more clinically relevant measure, as it accounts for the changes in risk over time. The purpose of this study was to estimate CS for ovarian cancer patients through analysis of large-scale cancer registry data. Methods: Ovarian cancer cases were extracted from the Surveillance, Epidemiology, and End Results (SEER 17) database from the National Cancer Institute (NCI) for patients diagnosed between 1988-2001. Five-year relative CS calculations were performed with stratification by age, race, stage, histology, and grade for patients who had already survived up to 5 years from diagnosis. Results: The 5-year overall relative CS improved over time for up to 5 years after diagnosis for ovarian cancer patients. The largest gains in CS over time were seen for patients with advanced stage disease, poor grade, and serous and undifferentiated epithelioid histologies. For patients with stage IV disease, 5-year CS more than tripled over the first 5 years of surveillance (17%-56%). Among histological types, patients with undifferentiated epithelioid histology saw 5-year CS rise from 29% at diagnosis to 84% after 5 years. Conclusions: Prognosis improves over time for almost all groups of ovarian cancer patients. For ovarian cancer survivors, CS provides a more relevant measure of prognosis than conventional survival estimates that are made at the time of diagnosis.

KW - Epidemiologic methods

KW - Ovarian cancer

KW - Prognosis

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=42749091238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749091238&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.01.033

DO - 10.1016/j.ygyno.2008.01.033

M3 - Article

VL - 109

SP - 203

EP - 209

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -